25.4 C
New York
Saturday, June 13, 2026

Tag: identification

newssourceFORcompanyinformationcontent1marketreleases

Lynch Carpenter Investigates Velocity Risk Data Breach Impacting Tens of Thousands

PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Velocity Risk Underwriters, LLC (“Velocity Risk”) recently announced a cybersecurity incident, which impacted the personal information of tens of thousands of individuals.1 The information potentially impacted in the data breach includes individuals’ names, dates of birth, Social Security Numbers, financial information, and tax identification numbers.

Strength Building: How Strength Training Supplements Help You Build Muscle Mass and Keep Growing Stronger – CrazyBulk

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

Strength Building: How Strength Training Supplements Help You Build Muscle Mass and Keep Growing Stronger – CrazyBulk

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey. 

Mohawk Industries publie ses résultats financiers pour le deuxième trimestre 2025

CALHOUN, État de Géorgie, 26 juill. 2025 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE : MHK) annonce ce jour un bénéfice net de 147 millions de dollars et un bénéfice par action (« BPA ») de 2,34 dollars pour le deuxième trimestre 2025. Le bénéfice net ajusté ressort à 173 millions de dollars et le BPA ajusté à 2,77 dollars. À 2,8 milliards de dollars, le chiffre d’affaires net pour la période observée reste stable en données publiées, mais affiche une baisse de 0,8 % en données ajustées pour tenir compte des jours constants et des taux de change par rapport à l’exercice précédent. Au cours du deuxième trimestre 2024, la Société avait déclaré un chiffre d’affaires net de 2,8 milliards de dollars, un bénéfice net de 157 millions de dollars et un bénéfice par action de 2,46 dollars ; le bénéfice net ajusté s’élevait pour sa part à 192 millions de dollars et le BPA ajusté à 3,00 dollars.

Matrix Medical Network Announces Strategic Partnership with Molecular Testing Labs to Enhance In-Home Diagnostic Offerings

Leader In Delivering Home-Based Health and Care Services Partners with Laboratory Known for Quality, Reliability and Innovation NASHVILLE, Tenn., July 23, 2025 /PRNewswire/ -- Matrix Medical...

Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030

"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms." BOSTON,...

Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030

"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms." BOSTON,...

InventHelp Inventor Develops Modified Bra for Storing Items (MBQ-647)

PITTSBURGH, July 25, 2025 /PRNewswire/ -- "I wanted to create a better way to carry money, identification, keys, and other valuables within a bra,"...

Valeura Energy Inc.: Strategic Farm-in Agreement with PTTEP

Major Offshore Acreage Expansion Creates New Growth Platform in the Gulf of Thailand 
Major Offshore Acreage Expansion Creates New Growth Platform in the Gulf of Thailand

Lear Reports Second Quarter 2025 Results

SOUTHFIELD, Mich., July 25, 2025 /PRNewswire/ -- Lear Corporation (NYSE: LEA), a global automotive technology leader in Seating and E-Systems, today reported results for the second...

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”2

Mohawk Industries Reports Q2 2025 Results

CALHOUN, Ga., July 24, 2025 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) today announced second quarter 2025 net earnings of $147 million and earnings per share (“EPS”) of $2.34; adjusted net earnings were $173 million, and adjusted EPS was $2.77. Net sales for the second quarter of 2025 were $2.8 billion, essentially flat as reported and a decrease of 0.8% adjusted for constant days and exchange rates versus the prior year. During the second quarter of 2024, the Company reported net sales of $2.8 billion, net earnings of $157 million and earnings per share of $2.46; adjusted net earnings were $192 million, and adjusted EPS was $3.00.

Johnson & Johnson showcases latest advancements in Alzheimer’s research at AAIC 2025

Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection New findings highlight the central role of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsIdentification

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers